(Tuesday, 7/31/2018) 7:30 AM - 9:30 AM
Room: Davidson Ballroom B
Purpose: Recent advances in deep neural networks (DNN) have opened the doors toward application of DNN for automatic image segmentation. We have evaluated a DNN-based algorithm for automatic segmentation of the prostate gland on a large cohort of patient images.
Methods: Planning-CT (pCT) datasets for 1114 prostate cancer patients were retrospectively selected and divided into 2 groups. Group A contained 1104 datasets, with prostate gland contours delineated by physician on each dataset. Among these image sets, 964 were used for training/validation and 140 were used for testing. Group B contained 10 datasets; each including prostate contours delineated by 5 independent physicians, and consensus contour generated with the STAPLE method in CERR to combine the 5 physician contours. All images were resampled to spatial resolution of 1mmX1mmX1.5mm. A region(128X128X64) was selected in the vicinity of the prostate to train a DNN. The top performing DNN was chosen based on validation results, and used to segment the prostate on all testing images. Results were compared between DNN and physician-generated contours using Dice coefficient(DSC).
Results: Mean DSC between automatic DNN-based prostate segmentation and physician-delineated contours for test data in group A was 0.85+0.06 [range=0.65, 0.93]. Mean DSC between automatic DNN-based prostate segmentation and the 5 physician contours in group B was 0.85+0.04 [range=0.80, 0.91]. Mean DSC between automatic DNN-based prostate segmentation and the consensus contour in group B was 0.88+0.03 [range=0.82, 0.92].
Conclusion: A deep-neural-network-based algorithm was used to automatically segment the prostate for a large cohort of prostate cancer patients. Furthermore, the DNN prostate segmentations were compared to consensus contour for a smaller group of patients; the agreement between DDN segmentations and consensus contour was similar to the agreement reported in a previous study between clinician contours and consensus. Clinical use of DNN is promising, but further investigation is warranted.
Funding Support, Disclosures, and Conflict of Interest: Henry Ford Health System holds research agreements with Varian Medical Systems (Palo Alto, CA) and Philips Healthcare (Best, Netherlands).
Keywords
Not Applicable / None Entered.
Taxonomy
Not Applicable / None Entered.
Contact Email
